Sitemap
- Research & Development
- Science portfolio
- Managing the project portfolio
- Curing malaria
- Tackling resistance
- Blocking transmission
- Essential information for scientists
- R & D process
- OZ 439 - Interview with Dr Jörg Möhrle
- R&D Process Slideshow
- Open access Malaria Box
- Malaria box FAQs
- Malaria box citations and references
- Malaria box supporting information
- Malaria box terms and conditions
- 10th call for proposals
- Map: Malaria Box orders
- Access & Delivery
- MMV en franҫais
- Partnering
- MMV's partnership network
- Who we work with
- Who we work with
- The PDP model
- Product development partnership model
- Socially responsible agreements
- Delivering good, affordable drugs to those in need
- Partner Interviews
- Mahidol–Oxford Tropical Medicine Research Unit – Treating patients with severe malaria
- Overcoming the challenges of conducting clinical trials in India
- College of Medicine Malawi
- Guilin Pharmaceutical ─ Achieving prequalification at a price affordable in Africa
- MMV and Shin Poong
- Ozonide OZ439 – a winning network of partners
- How have you and your team most benefited from working with MMV as a scientific partner?
- OZ439 is now in Phase II clinical trials. What have been the main challenges the project team has encountered and how did you ov
- OZ493 - What attracted you to antimalarial drug research and, particularly, the ozonide project?
- What is most exciting about OZ439 as a future antimalarial?
- What was your main role in the project?
- DHODH ─ Academic brain meets industrial muscle
- Imperial College London - Guiding the development of transmission-blocking medicines
- Novartis Institute for Tropical Diseases ─ Feeding the drug development pipeline through the discovery of novel chemistry
- MMV and sigma-tau – bringing all the right ingredients together
- Achievements & Challenges
- About us
- Our mission & vision
- Organization and governance
- Our team
- Our donors
- Bill and Melinda Gates Foundation
- ExxonMobil
- Irish Aid
- National Institutes of Health (NIH)
- Netherlands Minister for Development Cooperation
- Rockefeller Foundation
- Spanish Agency for International Cooperation for Development (AECID)
- Swiss Agency for Development and Cooperation
- USAID - United States Agency for International Development
- United Kingdom Department for International Development (DFID)
- Wellcome Trust
- World Bank
- World Health Organization
- CRIMALDDI
- Newcrest Mining Limited
- Our history
- Jobs @ MMV
- Malaria and medicines
- FAQs
- Recommended links
- Contact us
- Subscribe
- Staff origins
- Newsroom
- News
- Press releases
- Films
- Video interviews
- Audio
- Publications
- Boilerplate
- Chaaria Blog
- Speech delivered by David Reddy, MMV's CEO at the GPARC launch
- Speech delivered by David Reddy, MMV's CEO at the signing of the ALMA-MMV MoU
- Coartem® Dispersible Slideshow
- Dr Ian Bathurst
- Events
- Access events
- Artemesinin events
- MMV events
- Science events
- 2011 World Malaria Day Theme: Achieving progress and impact
- ASTHM Symposium 2010 - Biographies
- Other events
- All advocacy events
- Past events
- Swiss Malaria Group Exhibition Slideshow
- 11th Annual Stakeholders Meeting Photo Slideshow
- MMV Stakeholders' Meeting Access Day Presentations
- MMV Stakeholders' Meeting Science Day Presentations
- Satellite Symposium - 7th European Congress on Tropical Medicine & International Health
- Invest in us
